Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 5
Submit an article Journal homepage
4,237
Views
24
CrossRef citations to date
0
Altmetric
Hepatology

The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records

Khurram JamilMallinckrodt Pharmaceuticals, Inc, Bedminster, NJ, USA;
,
Xingyue HuangMallinckrodt Pharmaceuticals, Inc, Bedminster, NJ, USA; Correspondence[email protected]
,
Belinda LovelaceFormerly of Mallinckrodt Pharmaceuticals, Inc, Bedminster, NJ, USA;
,
An T PhamFormerly of Mallinckrodt Pharmaceuticals, Inc, Bedminster, NJ, USA; ;University of Washington School of Pharmacy, Seattle, WA, USA;
,
Kunal LodayaBoston Strategic Partners, Inc Health Economics and Outcomes Research, Boston, MA, USA
&
George WanMallinckrodt Pharmaceuticals, Inc, Bedminster, NJ, USA;
Pages 421-429 | Received 08 Nov 2018, Accepted 25 Jan 2019, Published online: 04 Mar 2019

References

  • Russ KB, Stevens TM, Singal AK. Acute kidney injury in patients with cirrhosis. J Clin Transl Hepatol. 2015;3:195–204.
  • Testino G, Burra P, Bonino F, et al. Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statement. WJG. 2014;20:14642–51.
  • Allegretti AS, Ortiz G, Wenger J, et al. Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: a prospective cohort study. Int J Nephrol. 2015;2015: 108139.
  • US Department of Health and Human Services CfDCaP, National Center for Health Statistics. Summary Health Statistics: National Health Survey, 2015. National Center for Health Statistics: Centers for Disease Control and Prevention; 2015.
  • Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993; 105:229–236.
  • Arroyo V. New treatments for hepatorenal syndrome. Liver Transpl. 2000;6:287–289.
  • Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.
  • Ng CK, Chan MH, Tai MH, et al. Hepatorenal syndrome. Clin Biochem Rev. 2007;28:11–17.
  • Wadei HM, Mai ML, Ahsan N, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066–1079.
  • Lenz K. Hepatorenal syndrome-is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology. 2005;42:263–265.
  • Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 2002;122:1658–1676.
  • Heidemann J, Bartels C, Berssenbrugge C, et al. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract. 2015;2015:457613
  • Prowle JR, Kolic I, Purdell-Lewis J, et al. Serum creatinine changes associated with critical illness and detection of persistent renal dysfunction after AKI. Clin J Am Soc Nephrol. 2014;9:1015–1023.
  • Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176.
  • Cholongitas E, Burroughs AK. The evolution in the prioritization for liver transplantation. Ann Gastroenterol. 2012;25:6–13.
  • Cavallin M, Fasolato S, Marenco S, et al. The treatment of hepatorenal syndrome. Dig Dis. 2015;33:548–554.
  • Wong F. The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol. 2015;12:711–719.
  • Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfus. 2013;11(Suppl 4):s18–s25.
  • Runyon BA. Hepatorenal syndrome. UpToDate 2018 Feb 13, 2018 [cited 2018 Jun 11]; Available from: https://www.uptodate.com/contents/hepatorenal-syndrome
  • Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med. 2013;28:79–92.
  • Rice JB, White AG, Galebach P, et al. The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States. Curr Med Res Opin. 2017;33:1473–1480.
  • Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci. 2011;56:977–987.
  • Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–96.
  • Kumar R, Krishnamoorthy TL, Tan HK, et al. Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. Gastroenterol Rep (Oxf). 2015;3:122–127.
  • Hernaez R, Sola E, Moreau R, et al. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.
  • Horwitz LI, Grady JN, Cohen DB, et al. Development and validation of an algorithm to identify planned readmissions from claims data. J Hosp Med. 2015;10:670–677.
  • Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293–1298.
  • Mattos AZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28:345–351.
  • Suneja M, Tang F, Cavanaugh JE, et al. Population based trends in the incidence of hospital admission for the diagnosis of hepatorenal syndrome: 1998–2011. Int J Nephrol. 2016;2016:1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.